CNS Drugs

, Volume 26, Issue 5, pp 435–460 | Cite as


A Review of its Use in the Management of Bipolar Depression
  • Mark Sanford
  • Gillian M. Keating
Adis Drug Evaluation


Quetiapine (Seroquel®) is an orally administered atypical antipsychotic that is indicated for the treatment of schizophrenia and bipolar disorder, including bipolar depression. An extended-release (XR) formulation of quetiapine is also available. This review summarizes the pharmacological properties, efficacy and tolerability of quetiapine and quetiapine XR in patients with bipolar depression.

Quetiapine is an antagonist at both serotonin 5-HT2 and dopamine D2 receptors, and its antipsychotic effects are thought to stem from interactions at these receptors. The antidepressant effects of quetiapine are poorly understood, but may be related to antagonism of 5-HT2A receptors in cortical regions, partial agonism of 5-HT1A in the prefrontal cortex in association with increased extracellular dopamine release in the region, or to reduced synaptic reuptake of nor-adrenaline resulting from inhibition of the noradrenaline reuptake transporter by the quetiapine metabolite norquetiapine.

The efficacy and tolerability of quetiapine was evaluated in five 8-week, randomized, double-blind, placebo-controlled, multicentre or multinational trials in patients with a major depressive episode (MDE) associated with bipolar disorder. Across trials, monotherapy with oral quetiapine 300 or 600 mg/day (or quetiapine XR 300 mg/day) produced significantly greater improvements than placebo in depressive symptoms (primary endpoint), according to the change in the Montgomery-Asberg Depression Rating Scale total score. In general, quetiapine and quetiapine XR were also associated with significantly higher MDE response and remission rates than placebo. Across trials, quetiapine and quetiapine XR produced significantly greater improvements in global severity of illness scores than placebo, according to changes in the Clinical Global Impressions scale score. There were no differences in treatment outcomes between quetiapine 300 mg/day and 600 mg/day dosage groups.

Patients with bipolar depression who responded to quetiapine during two 8-week acute treatment trials also benefited from continuing quetiapine therapy for up to 52 weeks. Compared with quetiapine responders randomized to placebo, quetiapine responders who continued quetiapine 300 or 600 mg/day had a significantly reduced risk of recurrence of any mood events and of depression mood events, but not of hypomanic/manic events.

In a randomized, double-blind, placebo-controlled trial, quetiapine maintenance therapy for up to 104 weeks was more efficacious than placebo or lithium in prolonging the time to recurrence of any mood event (primary endpoint). Patients in this trial had bipolar I disorder with mania, depression or a mixed episode as the index episode, and the trial included only patients who were responsive to acute phase quetiapine, which may have introduced a positive bias in favour of quetiapine over lithium during maintenance therapy.

Quetiapine 300 or 600 mg/day and quetiapine XR 300 mg/day was generally well tolerated in patients with bipolar depression, with most treatment-emergent adverse events being of mild to moderate severity. The most frequent adverse events occurring during the acute treatment phase were dry mouth, sedation, somnolence, dizziness (quetiapine and quetiapine XR), constipation (quetiapine) and increased appetite (quetiapine XR). Extrapyramidal symptoms (EPS) occurred across quetiapine and placebo groups, but there were no significant differences between quetiapine and placebo recipients on objective measures of EPS and akathisia. In some trials, quetiapine recipients experienced significantly greater weight gain than placebo recipients. Across trials, some quetiapine recipients had clinically relevant increases in blood glucose or lipid parameters, although these also occurred in patients from other treatment groups. The clinical significance of these changes is uncertain.

In conclusion, quetiapine and quetiapine XR are valuable additions to the first-line treatments for bipolar depression. Further head-to-head trials of quetiapine versus other drug regimens that are effective in bipolar depression would be of considerable interest.


Bipolar Disorder Olanzapine Paroxetine Quetiapine Major Depressive Episode 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington,DC: American Psychiatric Association, 2000Google Scholar
  2. 2.
    Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005 Jun; 62: 593–602PubMedCrossRefGoogle Scholar
  3. 3.
    Kupfer DJ. The increasing medical burden in bipolar disorder. JAMA 2005 May 25; 293(20): 2528–30PubMedCrossRefGoogle Scholar
  4. 4.
    Ösby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001 Sep; 58(9): 844–50PubMedCrossRefGoogle Scholar
  5. 5.
    Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002 Jun; 59(6): 530–7PubMedCrossRefGoogle Scholar
  6. 6.
    Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003 Mar; 60(3): 261–9PubMedCrossRefGoogle Scholar
  7. 7.
    Pharmacotherapy of psychosis and mania. In: Brunton LL, editor. Goodman & Gilman’s The pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill, 2006; 461–500Google Scholar
  8. 8.
    Nierenberg AA. An analysis of the efficacy of treatments for bipolar depression. J Clin Psychiatry 2008; 69 Suppl. 5:4–8PubMedGoogle Scholar
  9. 9.
    Cruz N, Sanchez-Moreno J, Torres F, et al. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int J Neuropsycho-pharmacol 2010 Feb; 13(1): 5–15CrossRefGoogle Scholar
  10. 10.
    Van Lieshout RJ, MacQueen GM. Efficacy and acceptability of mood stabilisers in the treatment of acute bipolar depression: systematic review. Br J Psychiatry 2010 Apr; 196(4): 266–73PubMedCrossRefGoogle Scholar
  11. 11.
    AstraZeneca. Seroquel® (quetiapine): summary of product characteristics [online]. Available from URL: [Accessed 2010 Jun 24]
  12. 12.
    AstraZeneca. Seroquel® (quetiapine fumarate) tablets: prescribing information [online]. Available from URL: [Accessed 2010 Jun 24]
  13. 13.
    AstraZeneca. Seroquel XR® (quetiapine fumarate) extended-release tablets: prescribing information [online]. Available from URL: [Accessed 2010 Jun 24]
  14. 14.
    AstraZenica Pharmaceuticals UK Ltd. Seroquel® XL 50 mg, 200 mg, 300 mg, 400 mg prolonged-release tablets: summary of product characteristics [online]. Available from URL: [Accessed 2010 Jul 5]
  15. 15.
    Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001 Mar; 158(3): 360–9PubMedCrossRefGoogle Scholar
  16. 16.
    Yatham LN, Goldstein JM, Vieta E, et al. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry 2005; 66 Suppl. 5: 40–8PubMedGoogle Scholar
  17. 17.
    McIntyre RS, Soczynska JK, Woldeyohannes HO, et al. A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmacother 2007 Jun; 8(9): 1211–9PubMedCrossRefGoogle Scholar
  18. 18.
    Keating GM, Robinson DM. Quetiapine: a review of its use in the treatment of bipolar depression. Drugs 2007; 67(7): 1077–95PubMedCrossRefGoogle Scholar
  19. 19.
    Jensen NH, Rodriguiz RM, Caron MG, et al. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine’s antidepressant activity. Neuropsycho-pharmacology 2008 Sep; 33(10): 2303–12CrossRefGoogle Scholar
  20. 20.
    Nyberg S, Takano A, Jucaite A, et al. PET-measured occupancy of the norepinephrene transporter by extended release quetiapine fumarate (quetiapine XR) in brains of healthy subjects [abstract no. P.1.e.019]. Eur Neuropsy-chopharmacol 2008; 18 Suppl. 4: s270CrossRefGoogle Scholar
  21. 21.
    Datto C, Berggren L, Patel JB, et al. Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects. Clin Ther 2009 Mar; 31(3): 492–502PubMedCrossRefGoogle Scholar
  22. 22.
    Gefvert O, Lundberg T, Wieselgren IM, et al. D2 and 5HT2A receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol 2001 Apr; 11(2): 105–10PubMedCrossRefGoogle Scholar
  23. 23.
    Mamo DC, Uchida H, Vitcu I, et al. Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study. J Clin Psychiatry 2008 Jan; 69(1): 81–6PubMedCrossRefGoogle Scholar
  24. 24.
    Newcomer JW, Ratner RE, Eriksson JW, et al. A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. J Clin Psychiatry 2009 Apr; 70(4): 487–99PubMedCrossRefGoogle Scholar
  25. 25.
    Montgomery SA. The under-recognized role of dopamine in the treatment of major depressive disorder. Int Clin Psychopharmacol 2008 Mar; 23(2): 63–9PubMedCrossRefGoogle Scholar
  26. 26.
    Sparshatt A, Jones S, Taylor D. Quetiapine: dose-response relationship in schizophrenia. CNS Drugs 2008; 22(1): 49–68; discussion 69-72PubMedCrossRefGoogle Scholar
  27. 27.
    De Vane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 2001; 40(7): 509–22CrossRefGoogle Scholar
  28. 28.
    Figueroa C, Brecher M, Hamer-Maansson JE, et al. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry 2009 Mar 17; 33(2): 199–204PubMedCrossRefGoogle Scholar
  29. 29.
    Aichhorn W, Marksteiner J, Walch T, et al. Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. Int Clin Psychopharmacol 2006 Mar; 21(2): 81–5PubMedCrossRefGoogle Scholar
  30. 30.
    Potkin SG, Thyrum PT, Alva G, et al. The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. J Clin Psychopharmacol 2002 Apr; 22(2): 121–30PubMedCrossRefGoogle Scholar
  31. 31.
    Potkin SG, Thyrum PT, Alva G, et al. Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. J Clin Psychopharmacol 2002 Apr; 22(2): 174–82PubMedCrossRefGoogle Scholar
  32. 32.
    Winter HR, DeVane CL, Figueroa C, et al. Open-label steady-state pharmacokinetic drug interaction study on coadministered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder. Hum Psychopharmacol 2007 Oct; 22(7): 469–76PubMedCrossRefGoogle Scholar
  33. 33.
    Potkin SG, Thyrum PT, Bera R, et al. Open-label study of the effect of combination quetiapine/lithium therapy on lithium pharmacokinetics and tolerability. Clin Ther 2002 Nov;24(11): 1809–23PubMedCrossRefGoogle Scholar
  34. 34.
    Wang J-S, Zhu H-J, Markowitz JS, et al. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl) 2006 Sep; 187(4): 415–23CrossRefGoogle Scholar
  35. 35.
    Calabrese JR, Keck Jr PE, MacFadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. The BOLDER Study Group. Am J Psychiatry 2005 Jul; 162(7): 1351–60CrossRefGoogle Scholar
  36. 36.
    Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). BOLDER II Study Group. J Clin Psychopharmacol 2006 Dec; 26(6): 600–9CrossRefGoogle Scholar
  37. 37.
    Suppes T, Datto C, Minkwitz M, et al. Effectiveness of the extended release formulation of quetiapine as mono-therapy for the treatment of acute bipolar depression. J Affect Disord 2010 Feb; 121(1–2): 106–15PubMedCrossRefGoogle Scholar
  38. 38.
    Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo-controlled study of quetiapine and lithium mono-therapy in adults in the acute phase of bipolar depression (EMBOLDEN I). EMBOLDEN I Investigators. J Clin Psychiatry 2010 Feb; 71(2): 150–62CrossRefGoogle Scholar
  39. 39.
    McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). EMBOLDEN II Investigators. J Clin Psychiatry 2010 Feb; 71(2): 163–74CrossRefGoogle Scholar
  40. 40.
    Young AH, McElroy SL, Olausson B, et al. A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder. World J Biol Psychiatry. Epub 2012 Mar 12Google Scholar
  41. 41.
    Weisler RH, Nolen WA, Neijber A, et al. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (trial 144: a randomized controlled study). J Clin Psychiatry 2011 Nov; 72(11): 1452–64PubMedCrossRefGoogle Scholar
  42. 42.
    Hamilton M. A rating scale for depression. J Neurol Neurosurg 1960; 23(1): 56–62CrossRefGoogle Scholar
  43. 43.
    Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133(5): 429–35PubMedCrossRefGoogle Scholar
  44. 44.
    Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Brit J Psychiat 1979 Apr; 134(4): 382–9PubMedCrossRefGoogle Scholar
  45. 45.
    Duru G, Fantino B. The clinical relevance of changes in the Montgomery-Asberg Depression Rating Scale using the minimum clinically important difference approach. Curr Med Res Opin 2008; 24(5): 1329–35PubMedCrossRefGoogle Scholar
  46. 46.
    Solvay Pharmaceuticals, Inc. Lithibid® (lithium carbonate slow-release) 300 mg tablets: prescribing information [online]: Available from URL: [Accessed 2010 Oct 21]
  47. 47.
    GlaxoSmithKline. Paxil® (paroxetine hydrochloride) tablets and oral suspension: prescribing information [online]. Available from URL: us_paxil.pdf [Accessed 2010 Jun 25]
  48. 48.
    Guy W, editor. ECDEU assessment manual for psychopharmacology. Rockville (MD): US Department of Health, Education and Welfare, 1976Google Scholar
  49. 49.
    Cookson J, Keck Jr PE, Ketter TA, et al. Number needed to treat and time to response/remission for quetiapine monotherapy efficacy in acute bipolar depression: evidence from a large, randomized, placebo-controlled study. Int Clin Psychopharmacol 2007 Mar; 22(2): 93–100PubMedCrossRefGoogle Scholar
  50. 50.
    Sheehan DV. The anxiety disease. New York: Scribner, 1983Google Scholar
  51. 51.
    Hirschfeld RMA, Weisler RH, Raines SR, et al. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. BOLDER Study Group. J Clin Psychiatry 2006 Mar; 67(3): 355–62CrossRefGoogle Scholar
  52. 52.
    Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50–5PubMedCrossRefGoogle Scholar
  53. 53.
    Endicott J, Rajagopalan K, Minkwitz M, et al. A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: improvements in quality of life. Int Clin Psychopharmacol 2007; 22(1): 29–37PubMedCrossRefGoogle Scholar
  54. 54.
    Suppes T, Hirschfeld RM, Vieta E, et al. Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebo-controlled studies. World J Biol Psychiatry 2008; 9(3): 198–211PubMedCrossRefGoogle Scholar
  55. 55.
    Vieta E, Calabrese JR, Goikolea JM, et al. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2007 Jun; 9(4): 413–25PubMedCrossRefGoogle Scholar
  56. 56.
    Posner K, Oquendo MA, Gould M, et al. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA’s pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 2007 Jul; 164(7): 1035–43PubMedCrossRefGoogle Scholar
  57. 57.
    National Institute for Health and Clinical Excellence. Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care (NICE clinical guideline 38) [online]. Available from URL: [Accessed 2010 Jun 23]
  58. 58.
    The Royal Australian and New Zealand College of Psychiatrists. Bipolar disorder: Australian treatment guide for consumers and carers [online]. Available from URL: [Accessed 2010 Jul 15]
  59. 59.
    Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009 May; 11(3): 225–55PubMedCrossRefGoogle Scholar
  60. 60.
    Hirschfeld RMA. Guideline watch: practice guideline for the treatment of patients with bipolar disorder. 2nd ed. American Psychiatric Association [online]. Available from URL: [Accessed 2010 Jul 15]
  61. 61.
    Thase ME. Quetiapine monotherapy for bipolar depression. Neuropsychiatr Dis Treat 2008 Feb; 4(1): 11–21PubMedGoogle Scholar
  62. 62.
    Baldessarini RJ. Treatment research in bipolar disorder: issues and recommendations. CNS Drugs 2002; 16(11): 721–9PubMedCrossRefGoogle Scholar
  63. 63.
    Tondo L, Baldessarini RJ. Long-term lithium treatment in the prevention of suicidal behaviour in bipolar disorder patients. Epidemiol Psichiatr Soc 2009 Jul; 18(3): 179–83PubMedGoogle Scholar
  64. 64.
    DelBello MP, Chang K, Welge JA, et al. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord 2009 Aug; 11(5): 483–93PubMedCrossRefGoogle Scholar
  65. 65.
    Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders. Arch Gen Psychiatry 2004 Aug; 61(8): 807–16PubMedCrossRefGoogle Scholar
  66. 66.
    Mehta DK, editor. British national formulary. 2006 ed. London: BMJ Publishing Group Ltd., 2006Google Scholar
  67. 67.
    Haddad PM, Sharma SG. Adverse effects of atypical anti-psychotics. CNS Drugs 2007; 21(11): 911–36PubMedCrossRefGoogle Scholar
  68. 68.
    Woodward TC, Tafesse E, Quon P, et al. Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder. Pharmacoeconomics 2010; 28(9): 751–64PubMedCrossRefGoogle Scholar
  69. 69.
    Meier G, von Maltzahn R, Parkinson BT. Cost-effectiveness of quetiapine extended-release versus paroxetine and lithium in acute bipolar depression [abstract no. PMH48]. 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2009 Oct 24–27; ParisGoogle Scholar
  70. 70.
    Meier G, Edwards SJ, von Maltzahn R. Cost-effectiveness of quetiapine extended release versus other atypical anti-psychotics in acute bipolar depression [abstract no. PMH49]. 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2009 Oct 24–27; ParisGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  1. 1.AdisMairangi Bay, North Shore 0754, AucklandNew Zealand

Personalised recommendations